工艺研究与开发 MedKoo 作为 CRO 的优势之一是我们能够快速识别可扩展的工艺。快速实施客户的技术包或新合成的定制设计需要良好的科学和专家评估技能。 MedKoo 的科学家通常在非常短的交付周期内工作，经过培训可以快速集中精力生产感兴趣的化合物。世界一流的工艺研发是稳健、可靠的药物开发和商业流程的基础。 MedKoo 通过以下领域对这一专业知识进行了大量明智的投资：• 工艺表征和验证• 反应优化以降低成本和最大化产量• 催化剂筛选和优化• 结晶研究• 盐选择和多晶型物筛选• API 合成以支持 GLP从毒理学到临床研究• 关键工艺参数评估• 杂质分析和分离定制合成定制有机合成是我们最强的专长之一。我们拥有一支受过良好教育和广泛训练的合成化学团队，能够每年合成 300-400 种复杂药物。 MedKoo 的化学家可以快速合成新化合物，让您的研究步入正轨。随着该行业越来越需要外包分子合成，大型制药公司和新兴药物发现公司都转向 MedKoo，将边际产量的多个合成步骤转化为产量更高的实用化学。我们的成功来自我们具有竞争力的价格、我们对客户服务的坚定承诺以及我们科学家的才能和经验。我们的定制合成包括但不限于：(a)。合成您自己的候选药物 (b)。参考/竞争化合物的合成 (c)。新发表化合物的合成(d)。合成路线设计和路线侦察(e)。合成工艺开发；改进与优化化（f）。批量合成和制造出于成本效益的原因，我们要求定制合成的最低订单量为 1g。\"条款和条件”请参见网页：https://www.medkoo.com/page/terms_and_conditions删除您的专利化合物MedKoo 的政策始终是绝不故意侵犯任何人的知识产权。一如既往，我们高度尊重知识产权。我们打算继续做一个负责任和有道德的供应商，并与科学界合作。如果您发现您的专利分子列在我们的网页上，并且您希望将其删除，请发送电子邮件至 sales@medkoo.com 或致电我们，一旦收到您的请求，我们将立即采取行动停止或从我们的网站上删除该分子。无需通过专利代理人发送信件。LicensingMedKoo Bioscience 乐于与科学家合作，将新发现带出实验室并进入商业领域。小分子和肽是我们的传统专业领域，但适用于临床前研究的任何类型的生物探针或其他材料都具有潜在的利益。MedKoo 的政策一直是绝不故意侵犯任何人的知识产权。我们打算继续做一个负责任和有道德的供应商，并与科学界合作。 MedKoo 产品经理与大学和制药公司的许多科学家成功合作，将生命科学工具引入全球研究界。我们现有的合同涵盖保密和不披露、研究、材料转让、许可和供应协议。我们的服务也适用于希望在需要时保留对其发明分发的控制权的发明家和专利持有人。我们的营销和销售es 团队与我们的国际分销商网络合作，以确保尽可能广泛的商业覆盖。特别委托的文献、我们的网站和我们的贸易展览计划的组合将确保您的材料永久展示给我们全球的生命科学客户。要提交有关潜在许可候选人的信息或讨论许可机会，请发送电子邮件至我们的许可团队：cchen@medkoo.com 从 MedKoo 网站删除您的专利产品我们高度尊重专利权。如果我们无意中在我们的网站上列出了您的专利分子，而您想将其删除，请发送电子邮件至 cchen@medkoo.com 或 sales@medkoo.com。我们将立即停止并移除所要求的分子。无需通过您的专利代理人发送信件。 Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

MedKoo Cat#: 100012 Name: Aclarubicin hydrochloride CAS#: 75443-99-1 (HCl) Chemical Formula: C42H54ClNO15 Exact Mass: 847.32 Molecular Weight: 848.34 Elemental Analysis: C, 59.46; H, 6.42; Cl, 4.18; N, 1.65; O, 28.29

Related CAS #: 75443-99-1 (HCl); 57576-44-0 (free base).

Synonym: Aclacinomycin; Aclacinomycin A hydrochloride; Aclarubicin Hydrochloride; Antibiotic MA144A1. Aclacin; Aclacinomycine; Aclacinon; Aclaplastin; Jaclacin. ACM; ACMA. MA144A1

IUPAC/Chemical Name: (1R,2R,4S)-methyl 4-(((2R,5S,6S)-4-(dimethylamino)-5-(((2S,4S,5S,6S)-4-hydroxy-6-methyl-5-(((2R,6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate hydrochloride

InChi Key: KUSMIBXCRZTVML-ZRMZNYNWSA-N

InChi Code: InChI=1S/C42H53NO15.ClH/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29;/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3;1H/t18-,19-,20-,24?,27-,28-,29-,30-,31-,35-,39+,40+,42+;/m0./s1

SMILES Code: O=C([C@H]1[C@@](O)(CC)C[C@H](O[C@H]2CC(N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC([C@H](C)O4)=O)[C@H](C)O3)[C@H](C)O2)C5=C(O)C6=C(C(C7=CC=CC(O)=C7C6=O)=O)C=C15)OC.[H]Cl

Technical Data

Appearance: Red solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code: 293490

Additional Information

       

References

 1: Shin DH, Choi KS, Park SA, Cho BS, Lee HS, Ryu JS, Kim TY, Lee CK, Song S, Chung YB. Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells. Arch Pharm Res. 2008 Oct;31(10):1355-61. Epub 2008 Oct 29. PubMed PMID: 18958428.

2: Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother Pharmacol. 2008 Apr;61(5):739-49. Epub 2007 Jun 27. PubMed PMID: 17594094.

3: Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, Geng MY, Cai YJ, Ding J. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol Cancer Ther. 2007 Feb;6(2):484-95. PubMed PMID: 17308047.

4: Koceva-Chyła A, Wiecławska B, Jóźwiak Z, Bryszewska M. Combined effect of low-power laser irradiation and anthraquinone anticancer drug aclarubicin on survival of immortalized cells: Comparison with mitoxantrone. Cell Biol Int. 2006 Aug;30(8):645-52. Epub 2006 Apr 25. PubMed PMID: 16857396.

5: Goodell JR, Madhok AA, Hiasa H, Ferguson DM. Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity. Bioorg Med Chem. 2006 Aug 15;14(16):5467-80. Epub 2006 May 19. PubMed PMID: 16713270.

6: Liao Z, Thibaut L, Jobson A, Pommier Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol Pharmacol. 2006 Jul;70(1):366-72. Epub 2006 Apr 17. PubMed PMID: 16618796.

7: Koceva-Chyła A, Jedrzejczak M, Skierski J, Kania K, Jóźwiak Z. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis. 2005 Dec;10(6):1497-514. PubMed PMID: 16215684.

8: Wang T, Chen FY, Gu CH, Zhong H, Teng Y, Ouyang RR. [Transfection of HL-60 cells with CYP3A5 gene induces drug-resistant phenotype]. Zhonghua Zhong Liu Za Zhi. 2005 Aug;27(8):461-4. Chinese. PubMed PMID: 16188140.

9: Ryu JS, Lee HS, Hong YS, Lee JJ, Sohn UD, Kim TY. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin). Cancer Chemother Pharmacol. 2006 Jun;57(6):811-8. Epub 2005 Sep 21. Erratum in: Cancer Chemother Pharmacol. 2007 Feb;59(2):283-4. PubMed PMID: 16175393.

10: Lehmann M, Vilar Kde S, Franco A, Reguly ML, Rodrigues de Andrade HH. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. PubMed PMID: 15141364.